Latest Conference Articles

Larry Anderson, MD, PhD, discusses outcomes with idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma, as demonstrated in the phase 2 KarMMa trial.

Brad S. Kahl, MD, discusses the potential utility of BTK inhibitor–based combinations in the frontline setting of mantle cell lymphoma.

Vaishali Sanchorawala, MD, discusses the impact of renal and cardiac response on survival in patients with light chain amyloidosis. 

Srdan Verstovsek, MD, PhD, discusses ongoing research in myelofibrosis-related anemia.

Catherine Callaghan Coombs, MD, discusses the efficacy results of the ongoing phase 1/2 BRUIN study with pirtobrutinib in chronic lymphocytic leukemia.

Jorge E. Cortes, MD, discusses emerging therapies in chronic myeloid leukemia.

David J. Pinato, MD, discusses guidelines for toxicity management in hepatocellular carcinoma (HCC).

Arndt Vogel, MD, discusses the utility of frontline lenvatinib or sorafenib in hepatocellular carcinoma.

Amit Singal, MD, discusses the results of a study evaluating the utilization of a mailed surveillance outreach program in hepatocellular carcinoma.

Nicole Rich, MD, discusses the prevalence of cachexia in hepatocellular carcinoma.

Karen L. Kelly, MD, discusses overcoming osimertinib resistance in patients with non–small cell lung cancer through the use of bispecific antibodies.

Karen L. Reckamp, MD, discusses the significance of the final results of the ALTA trial in patients with ALK-positive non–small cell lung cancer.

Maria E. Arcila, MD, highlights important considerations for selecting among molecular diagnostic tests for patients with lung cancer.

David R. Gandara, MD, discusses how minimal residual disease testing might be incorporated into lung cancer clinical practice.

Sukhmani K. Padda, MD, discusses treatment selection following osimertinib resistance in patients with non–small cell lung cancer.

Sandip P. Patel, MD, discusses the potential of combining PARP inhibitors with immunotherapy for patients with non–small cell lung cancer.

Sara M. Tolaney, MD, MPH, discusses tailoring HER2-directed therapies in the treatment of patients with breast cancer. 

Vinayak G. Wagaskar, MBBS, discusses potential explanations for a paradoxical relationship between obesity and outcomes observed in prostate cancer.

Evangelia Sereti, MSc, PhD, discusses the next steps with the combination of NOV202 and olaparib in BRCA1/2-mutated prostate cancer.

Evangelia Sereti, MSc, PhD, discusses the preclinical efficacy of NOV202 plus olaparib in BRCA1/2-mutated prostate cancer cells.

Vinayak G. Wagaskar, MBBS, discusses the rationale to evaluate the relationship between obesity paradigm and outcomes in prostate cancer.

Aditya Bardia, MD, MPH, discusses ongoing research with amcenestrant and palbociclib in estrogen receptor–positive, HER2-negative advanced breast cancer.

Sarat Chandarlapaty, MD, PhD, highlights responses to amcenestrant and palbociclib in patients with estrogen receptor–positive, HER2-negative metastatic breast cancer, as seen in the phase 1/2 AMEERA 1 trial.

Margaret von Mehren, MD, discusses outcomes with ribociclib and everolimus in dedifferentiated liposarcoma, as seen in the phase 2 SAR-096 trial.

Ruben A. Mesa, MD, discusses the importance of achieving transfusion independence with momelotinib in myelofibrosis.

OncLive sits down with Sandy Wong, MD; Neal Shore, MD; and Loretta Nastoupil, MD, to share the the insight on data in multiple myeloma, prostate cancer, and non-Hodgkin lymphoma at the 2021 ASCO Annual Meeting.

Mark Christopher Markowski, MD, PhD, discusses the safety and efficacy of VERU-111 in patients with metastatic castration-resistant prostate cancer.

Suresh S. Ramalingam, MD, FASCO, discusses updated data with mobocertinib in EGFR exon 20 insertion–positive advanced non–small cell lung cancer.

John Raymond Zalcberg, discusses the efficacy of intra-patient dose escalation with ripretinib in patients with advanced gastrointestinal stromal tumors, as demonstrated in an analysis of the phase 3 INVICTUS trial.

Nazir Tannir, MD, FACP, discusses the efficacy of the combination of telaglenastat and cabozantinib in patients with metastatic renal cell carcinoma, as demonstrated in the phase 2 CANTATA trial.